PSCA and Oct-4 Expression in the Benign and Malignant Lesions of Gallbladder: Implication for Carcinogenesis, Progression, and Prognosis of Gallbladder Adenocarcinoma

Abstract

PSCA and Oct-4 have been thought as markers of cancer stem cells. Although overexpression of PSCA and Oct-4 in cancer has been reported, little is known about the clinical and pathological significance with PSCA and Oct-4 expression in gallbladder adenocarcinoma. In this study, overexpression of PSCA and Oct-4 was detected in gallbladder adenocarcinoma (54.6% and 55.6%). Less expression of PSCA and Oct-4 was detected in the pericancerous tissues (19.6% and 21.7%), gallbladder polyps (13.3% and 13.3%), and gallbladder epithelium with chronic cholecystitis (14.3% and 14.3%). The overexpression of PSCA and Oct-4 was significantly associated with differentiation, tumor mass, lymph node metastasis, invasion of gallbladder adenocarcinoma, and decreased overall survival. Our study suggested that overexpression of PSCA and Oct-4 might be closely related to the carcinogenesis, progression, metastasis, or invasive potential and prognosis of gallbladder carcinoma.

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

“…Prostate stem cell antigen (PSCA) is a glycosylphosphoinositolanchored cell surface antigen 20 that is overexpressed mainly in prostate cancer, 21 although its expression has also been reported in other tumors such as gallbladder adenocarcinoma 22 and gastric cancer. 23 Surprisingly, PSCA is frequently overexpressed in NSCLC, 20 although this requires confirmation.…”

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression

“…It is believed that this protein is associated with the IFNα/β mediated immune response [ 11 ]. Subsequent reports showed that PSCA is likewise up-regulated in other cancer entities, such as gallbladder, urinary bladder cancer, renal cell carcinoma, pancreatic cancer or glioma [ 12 – 16 ], while it is down-regulated in others, such as esophageal and gastric cancers [ 17 – 20 ]. The clinical utility of PSCA as a diagnostic marker or therapeutic target has been demonstrated in prostrate, pancreatic and bladder cancer.…”

Impact of DCC (rs714) and PSCA (rs2294008 and rs2976392) Gene Polymorphism in Modulating Cancer Risk in Asian Population

“…Prostate stem cell antigen (PSCA) is a member of Ly-6/Thy-1 family of glycosylphosphatidyl-inositol (GPI)-anchored cell-surface proteins having a crucial role in cell adhesion, proliferation, and survival [ 14 ]. PSCA was found to be aberrantly expressed in several human cancers, and since it has restricted expression in normal tissues, PSCA represents an ideal target for cancer diagnosis and therapy [ 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. Human PSCA gene maps on chromosome 8q24.2 containing 464 SNPs.…”